AVLN: Inhaled therapies with strong IP aim to transform pulmonary fibrosis treatment and market reach
Focused on inhaled therapies for pulmonary fibrosis, the company leverages a patented nebulizer and strong IP to address major unmet needs in a large market. Lead candidates show improved tolerability and efficacy, with pivotal data expected next year and a robust pipeline advancing.Based on Avalyn…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.